Adenovirus Vector Manufacturing Platform Using CIMmultus® QA Column To Produce Safer Vaccines Cheaper

By K. Vrabec, H. Jug, A. Mavri, I. Petrovic Koshmak, V. Fujs, M. Leskovec, and A. Štrancar

After two decades, adenovirus has garnered renewed attention and is now employed as a delivery vehicle for COVID-19 vaccines. To reduce vaccine side effects, ensuring the purity of the virus is of utmost importance. Consequently, there is a continuous need for refining vaccine purity and enhancing impurity detection methods. In this study, we present a second-generation purification procedure for adenoviral vectors based on monolith chromatography, utilizing CIMmultus® QA and the accompanying analytical tools. This novel industrial process secures safer products and enhances purity at higher yields. Large-scale vaccine manufacturing during the pandemic represents significant challenges, primarily in terms of production time and costs. The high capacity of the CIMmultus® QA columns utilized in this process effectively overcomes the raw material supply bottlenecks.